Walid Abi-Saab - Sep 27, 2023 Form 3 Insider Report for uniQure N.V. (QURE)

Role
Chief Medical Officer
Signature
/s/ Jeannette Potts, Attorney-in-Fact
Stock symbol
QURE
Transactions as of
Sep 27, 2023
Transactions value $
$0
Form type
3
Date filed
10/2/2023, 09:50 PM
Next filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding QURE Ordinary Shares 67.2K Sep 27, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding QURE Stock Option (Right to Buy) Sep 27, 2023 Ordinary Shares 116K $11.47 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted 67,200 restricted share units in connection with the Reporting Person's appointment as Chief Medical Officer of the Issuer. The restricted share units were granted as an inducement grant pursuant to Nasdaq listing rule 5635(c)(4). Each restricted share unit represents the contingent right to receive one ordinary share of the Issuer. The restricted share units vest in three approximately equal annual installments, with the first vesting date to occur on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.
F2 The option vests over four years, with 25% of the shares underlying such option vesting on June 26, 2024 (the first anniversary of the date of grant), and 6.25% of the shares underlying such option vesting quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney